• Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics to evaluate its PH1 RNA splicing modulator ADC payload with Whitehawk’s TOP1i ADC platform.
• Planned preclinical studies will test dual-payload combinations for synergy, aiming to generate data to support next-generation ADC development opportunities.
• The partnership positions Akari’s PH1 platform for broader use beyond conventional ADC payload approaches as industry demand shifts toward differentiated payload innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220840PRIMZONEFULLFEED9766306) on July 22, 2026, and is solely responsible for the information contained therein.